ReviewSeminars in oncology2011
Personalized colon cancer care in 2010.
Review in Seminars in oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Identification of a Novel Five-Gene Signature as a Prognostic and Diagnostic Biomarker in Colorectal Cancers.International journal of molecular sciences · 2022Article
- Microwave Ablation in the Proximity of Surgical Clips: Is there a Safety Issue?Cardiovascular and interventional radiology · 2020Article
- c-Cbl Expression Correlates with Human Colorectal Cancer Survival and Its Wnt/β-Catenin Suppressor Function Is Regulated by Tyr371 Phosphorylation.The American journal of pathology · 2018Observational
- microRNA-374a suppresses colon cancer progression by directly reducing CCND1 to inactivate the PI3K/AKT pathway.Oncotarget · 2016Article
- Non-invasive diagnostic imaging of colorectal liver metastases.World journal of radiology · 2015Review
- Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.Molecular oncology · 2015Review
- Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases.International journal of colorectal disease · 2014Article
- The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.Investigational new drugs · 2014Article
- Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer.British journal of cancer · 2014Article
- MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer.Cancer cell · 2014Article
- Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?Virchows Archiv : an international journal of pathology · 2014Review
- Future directions for monitoring treatment response in colorectal cancer.Journal of Cancer · 2014Review
- Unsupported off-label chemotherapy in metastatic colon cancer.BMC health services research · 2012Article
- Meeting the biologic challenge of colorectal metastases.Clinical & experimental metastasis · 2012Review
- High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer.Cellular oncology (Dordrecht, Netherlands) · 2012Article
- Article
- Personalized medicine and cancer.Journal of personalized medicine · 2012Review
- The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study.The oncologist · 2012Article
- T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology.Clinical & developmental immunology · 2011Review
- Update on the role of imaging in management of metastatic colorectal cancer.Radiographics : a review publication of the Radiological Society of North America, IncReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Colon cancer (CC) therapies have improved patient outcomes significantly over the last decades in both the adjuvant and metastatic settings. With the introduction of a number of novel agents, both traditional chemotherapies and biologically targeted agents, the need to identify subgroups that are likely and not likely to respond to a particular treatment regimen is paramount. This will allow patients who are likely to benefit to receive optimal care, while sparing those unlikely to benefit from unnecessary toxicity and cost. With the identification of several novel biomarkers and a variety of technologies to interrogate the genome, we already are able to rapidly study patient tumor or blood samples and normal tissues to generate a large dataset of aberrations within the cancer. How to digest this complex information to obtain accurate, reliable, and meaningful results that will allow us to provide truly personalized care for CC patients is just starting to be addressed. In this article, we briefly review the history of CC treatment, with an emphasis on current clinical standards that incorporate a "personalized medicine" approach. We then review strategies that will potentially improve our ability to individualize therapy in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.